Vascular closure devices market to reach USD 3.25 billion by 2032 with 7.85% CAGR

From GlobeNewswire: 2025-06-23 08:30:00

The Vascular Closure Devices Market was valued at USD 1.78 billion in 2024 and is projected to reach USD 3.25 billion by 2032, with a CAGR of 7.85% from 2025 to 2032. Factors driving growth include a preference for minimally invasive procedures, demand for early ambulation, and technological advancements in closure devices.

The U.S. vascular closure devices market size was USD 0.52 billion in 2024 and is expected to reach USD 0.84 billion by 2032. Growth is fueled by the increasing incidence of cardiovascular diseases, a high number of catheter-based procedures, and supportive reimbursement methods.

Vascular closure devices (VCDs) are increasingly used after diagnostic or interventional angiography to achieve hemostasis at the access site, reduce complications, and improve patient comfort. The market is driven by the burden of peripheral and coronary artery disease, the growing geriatric population, and advancements in closure devices.

In 2024, active approximators accounted for the largest market share in the global vascular closure devices market, contributing 65.7%. These devices are preferred for their efficiency in mechanically sealing arteriotomy sites and reducing time to hemostasis, especially in complex interventions.

Cardiac interventions dominated the application segment in 2024, capturing over 48% of the total application share. This was supported by the increasing prevalence of coronary artery disease and a growing number of percutaneous coronary intervention (PCI) procedures.

North America held the largest share of the vascular closure devices market in 2024, led by the U.S. due to the high prevalence of CVD, advanced closure devices, and supportive reimbursement. The Asia Pacific region is the fastest-growing market due to rising awareness of minimally invasive surgeries and increased healthcare spending.

Recent developments in the market include Haemonetics releasing VASCADE MVP XL, Cordis receiving FDA approval for MYNX CONTROL VENOUS closure device, and Abbott launching the next-gen Perclose ProStyle closure system. These advancements aim to enhance hemostasis and improve patient outcomes.



Read more at GlobeNewswire: Vascular Closure Devices Market Set to Reach USD 3.25